240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey

IF 6.2 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes Pub Date : 2024-07-19 DOI:10.2337/db24-240-or

JENNIFER L. SHERR, KAITLIN HAGAN, RACHEL BHAK, MEGAN PETER, HUYEN NGUYEN, CHENKUN WANG, TATHABBAI PAKALAPATI, JORDAN SHERWOOD, TINA GUPTA, JASON L. GAGLIA, EMILEE M. CORNELIUS, KATHERINE S.M. CHAPMAN, WENDY WOLF, JEREMY PETTUS

{"title":"240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey","authors":"JENNIFER L. SHERR, KAITLIN HAGAN, RACHEL BHAK, MEGAN PETER, HUYEN NGUYEN, CHENKUN WANG, TATHABBAI PAKALAPATI, JORDAN SHERWOOD, TINA GUPTA, JASON L. GAGLIA, EMILEE M. CORNELIUS, KATHERINE S.M. CHAPMAN, WENDY WOLF, JEREMY PETTUS","doi":"10.2337/db24-240-or","DOIUrl":null,"url":null,"abstract":"Introduction & Objective: Longitudinal trends of glycemia and severe hypoglycemic events (SHE) among individuals with T1D are not well described, particularly in those using diabetes technologies (i.e., continuous glucose monitors [CGM], automated insulin delivery [AID]). Methods: An online survey recruited adults with T1D through the T1D Exchange Registry or online communities from February-April 2021. Overall, 2,044 individuals completed the survey and eligible participants were invited to complete follow-up survey from April-May 2023. Participants self-reported CGM use, insulin delivery method, HbA1c, impaired awareness of hypoglycemia (IAH), and SHE. Results: Of 1,999 eligible individuals, 1,056 completed the follow-up survey and were eligible for analysis (53% response rate; mean age: 46 y; mean T1D duration: 29 y; 71% female; 97% White). Most reported using CGMs at baseline (91.8%) and follow-up (94.4%), and use of AID increased (baseline: 53.5%; follow-up: 69.0%; Table). At baseline, 61.7% reported HbA1c &lt;7% vs. 67.4% at follow-up. Rates of IAH and SHE in the prior year were similar at both time points. Conclusion: Despite nearly universal CGM usage and increased adoption of AID, one-third of respondents did not achieve HbA1c targets and the proportion of respondents with IAH and SHE did not decline. These results highlight the need for innovative approaches to improve T1D care. Disclosure J.L. Sherr: Consultant; Medtronic. Advisory Panel; Medtronic, Insulet Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Vertex Pharmaceuticals Incorporated, MannKind Corporation, StartUp Health T1D Moonshot, Bigfoot Biomedical, Inc., Cecelia Health. Speaker's Bureau; Zealand Pharma A/S. K. Hagan: Employee; Vertex Pharmaceuticals Incorporated. R. Bhak: Employee; Vertex Pharmaceuticals Incorporated, Novartis Pharmaceuticals Corporation. M. Peter: None. H. Nguyen: None. C. Wang: Employee; Vertex Pharmaceuticals Incorporated. T. Pakalapati: None. J. Sherwood: Employee; Vertex Pharmaceuticals Incorporated. T. Gupta: Employee; Vertex Pharmaceuticals Incorporated. J.L. Gaglia: Consultant; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Vertex Pharmaceuticals Incorporated. Consultant; Avotres Inc., Imcyse, Diamyd Medical. E.M. Cornelius: None. K.S.M. Chapman: None. W. Wolf: None. J. Pettus: Consultant; Sanofi, Novo Nordisk, Diasome, Carmot Therapeutics, Inc., Kriya Therapeutics, Lilly Diabetes, Provention Bio, Inc. Funding Vertex Pharmaceuticals Incorporated","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"26 1","pages":""},"PeriodicalIF":6.2000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db24-240-or","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction & Objective: Longitudinal trends of glycemia and severe hypoglycemic events (SHE) among individuals with T1D are not well described, particularly in those using diabetes technologies (i.e., continuous glucose monitors [CGM], automated insulin delivery [AID]). Methods: An online survey recruited adults with T1D through the T1D Exchange Registry or online communities from February-April 2021. Overall, 2,044 individuals completed the survey and eligible participants were invited to complete follow-up survey from April-May 2023. Participants self-reported CGM use, insulin delivery method, HbA1c, impaired awareness of hypoglycemia (IAH), and SHE. Results: Of 1,999 eligible individuals, 1,056 completed the follow-up survey and were eligible for analysis (53% response rate; mean age: 46 y; mean T1D duration: 29 y; 71% female; 97% White). Most reported using CGMs at baseline (91.8%) and follow-up (94.4%), and use of AID increased (baseline: 53.5%; follow-up: 69.0%; Table). At baseline, 61.7% reported HbA1c <7% vs. 67.4% at follow-up. Rates of IAH and SHE in the prior year were similar at both time points. Conclusion: Despite nearly universal CGM usage and increased adoption of AID, one-third of respondents did not achieve HbA1c targets and the proportion of respondents with IAH and SHE did not decline. These results highlight the need for innovative approaches to improve T1D care. Disclosure J.L. Sherr: Consultant; Medtronic. Advisory Panel; Medtronic, Insulet Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Vertex Pharmaceuticals Incorporated, MannKind Corporation, StartUp Health T1D Moonshot, Bigfoot Biomedical, Inc., Cecelia Health. Speaker's Bureau; Zealand Pharma A/S. K. Hagan: Employee; Vertex Pharmaceuticals Incorporated. R. Bhak: Employee; Vertex Pharmaceuticals Incorporated, Novartis Pharmaceuticals Corporation. M. Peter: None. H. Nguyen: None. C. Wang: Employee; Vertex Pharmaceuticals Incorporated. T. Pakalapati: None. J. Sherwood: Employee; Vertex Pharmaceuticals Incorporated. T. Gupta: Employee; Vertex Pharmaceuticals Incorporated. J.L. Gaglia: Consultant; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Vertex Pharmaceuticals Incorporated. Consultant; Avotres Inc., Imcyse, Diamyd Medical. E.M. Cornelius: None. K.S.M. Chapman: None. W. Wolf: None. J. Pettus: Consultant; Sanofi, Novo Nordisk, Diasome, Carmot Therapeutics, Inc., Kriya Therapeutics, Lilly Diabetes, Provention Bio, Inc. Funding Vertex Pharmaceuticals Incorporated

查看原文本刊更多论文

240-OR： 1 型糖尿病成人血糖和严重低血糖纵向评估--在线调查

引言& 目的：对 T1D 患者的血糖和严重低血糖事件（SHE）的纵向趋势还没有很好的描述，尤其是对使用糖尿病技术（即连续血糖监测仪 [CGM]、自动胰岛素输送系统 [AID]）的患者。调查方法2021 年 2 月至 4 月期间，通过 T1D Exchange Registry 或在线社区对患有 T1D 的成人进行了在线调查。共有 2044 人完成了调查，并邀请符合条件的参与者在 2023 年 4 月至 5 月期间完成后续调查。参与者自我报告了 CGM 使用情况、胰岛素给药方法、HbA1c、低血糖意识受损 (IAH) 和 SHE。结果：在符合条件的 1,999 人中，1,056 人完成了跟踪调查并符合分析条件（53% 的回复率；平均年龄：46 岁；平均 T1D 病程：29 年；71% 为女性；97% 为白人）。大多数人报告在基线（91.8%）和随访（94.4%）时使用 CGM，AID 的使用有所增加（基线：53.5%；随访：69.0%；表）。基线时，61.7%的人报告 HbA1c &;lt;7%，而随访时为 67.4%。在两个时间点，上一年的 IAH 和 SHE 发生率相似。结论：尽管 CGM 的使用几乎得到普及，AID 的采用率也有所提高，但仍有三分之一的受访者未达到 HbA1c 目标，患有 IAH 和 SHE 的受访者比例并未下降。这些结果凸显了采用创新方法改善 T1D 护理的必要性。披露 J.L. Sherr：顾问；美敦力公司。顾问团；美敦力公司、Insulet 公司。发言人办公室；Insulet 公司。顾问团；Vertex Pharmaceuticals Incorporated、MannKind Corporation、StartUp Health T1D Moonshot、Bigfoot Biomedical, Inc.、Cecelia Health。Zealand Pharma A/S 发言人办公室。K. Hagan：雇员；Vertex Pharmaceuticals Incorporated。R. Bhak：Vertex Pharmaceuticals Incorporated、Novartis Pharmaceuticals Corporation 员工。M. Peter：无。H. Nguyen：H. Nguyen: None.C. Wang：Vertex Pharmaceuticals Incorporated 员工。T. Pakalapati：无。J. Sherwood：Vertex Pharmaceuticals Incorporated: Employee.T. Gupta：Vertex Pharmaceuticals Incorporated 员工。J.L. Gaglia：顾问；Vertex Pharmaceuticals Incorporated。顶点制药公司股票/股东顾问；Avotres Inc.、Imcyse、Diamyd Medical。E.M. Cornelius：无。K.S.M. Chapman：无。W. Wolf：无。J. Pettus：顾问；赛诺菲、诺和诺德、Diasome、Carmot Therapeutics, Inc.、Kriya Therapeutics、礼来糖尿病、Provention Bio, Inc.资助 Vertex 制药公司

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.